Special Issue "The Sphingolipid Pathway in Cancer"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 September 2019

Special Issue Editors

Guest Editor
Prof. Stuart Pitson

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide SA 5001, Australia
Website | E-Mail
Interests: sphingolipids; sphingosine kinase; lipid metabolism; cell signaling; acute myeloid leukaemia; multiple myeloma; glioblastoma
Guest Editor
Prof. Nigel Pyne

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St, Glasgow G40RE, Scotland, UK
Website | E-Mail
Interests: sphingolipids; sphingosine 1-phosphate; sphingosine kinase; dihydroceramide desaturase; sphingosine 1-phosphate receptors; solid tumors; hematological cancer; cell signaling; lipid metabolism
Guest Editor
Dr. Melissa Pitman

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide SA 5001, Australia
Website | E-Mail
Interests: sphingolipids; lipid kinases; drug discovery; biochemistry; protein–protein interactions; cell signaling; ovarian cancer

Special Issue Information

Dear Colleagues,

Sphingolipids have long been known to play critical roles in the properties of cellular membranes. Research over the last three decades, however, has shown a number of sphingolipids to also be important signaling molecules that regulate a wide array of biological processes. In particular, sphingolipids, including but not limited to the ceramides and sphingosine 1-phosphate, have been shown to be important regulators of cell fate, influencing cell survival and proliferation, as well as cell differentiation. For this reason, the sphingolipid pathway has garnered significant interest as a target for anticancer therapies.

This Special Issue of Cancers seeks reviews and original papers that examine the roles of the sphingolipid pathway and its various individual components in cancers. The objective is to highlight the current understanding of the regulation of sphingolipid metabolism and signaling, its impact on cancer initiation, progression and responses to therapy, including chemoresistance, and how this information may be exploited for therapeutic benefit.

Prof. Stuart Pitson
Prof. Nigel Pyne
Dr. Melissa Pitman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Sphingolipids
  • Ceramides
  • Sphingosine 1-phosphate
  • Cell signaling
  • Cancer
  • Apoptosis

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top